238 related articles for article (PubMed ID: 37511018)
1. Genetic Abnormalities in Extramedullary Multiple Myeloma.
McAvera R; Quinn J; Murphy P; Glavey S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511018
[TBL] [Abstract][Full Text] [Related]
2. Extramedullary disease in multiple myeloma.
Bansal R; Rakshit S; Kumar S
Blood Cancer J; 2021 Sep; 11(9):161. PubMed ID: 34588423
[TBL] [Abstract][Full Text] [Related]
3. [Research Progress on Multiple Myeloma with Extramedullary Disease].
Wang L; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):945-8. PubMed ID: 27342539
[TBL] [Abstract][Full Text] [Related]
4. Extramedullary disease in multiple myeloma: a systematic literature review.
Bladé J; Beksac M; Caers J; Jurczyszyn A; von Lilienfeld-Toal M; Moreau P; Rasche L; Rosiñol L; Usmani SZ; Zamagni E; Richardson P
Blood Cancer J; 2022 Mar; 12(3):45. PubMed ID: 35314675
[TBL] [Abstract][Full Text] [Related]
5. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
6. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis of the bone marrow microenvironment in extramedullary multiple myeloma patients.
Gregorova J; Vychytilova-Faltejskova P; Kramarova T; Knechtova Z; Almasi M; Stork M; Pour L; Kohoutek J; Sevcikova S
Neoplasma; 2022 Mar; 69(2):412-424. PubMed ID: 35037760
[TBL] [Abstract][Full Text] [Related]
8. Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma.
Liu Y; Jelloul F; Zhang Y; Bhavsar T; Ho C; Rao M; Lewis NE; Cimera R; Baik J; Sigler A; Sen F; Yabe M; Roshal M; Landgren O; Dogan A; Xiao W
Am J Surg Pathol; 2020 Jun; 44(6):838-848. PubMed ID: 32118627
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease.
Tucker SM; Zaihra T
Orbit; 2023 Dec; 42(6):603-611. PubMed ID: 36697375
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary Disease in Multiple Myeloma.
Jagosky MH; Usmani SZ
Curr Hematol Malig Rep; 2020 Apr; 15(2):62-71. PubMed ID: 32198576
[TBL] [Abstract][Full Text] [Related]
11. Identification of long noncoding RNA
Chen T; Sun Z; Cui Y; Ji J; Li Y; Qu X
Hematology; 2023 Dec; 28(1):2164449. PubMed ID: 36657019
[TBL] [Abstract][Full Text] [Related]
12. Extramedullary multiple myeloma.
Weinstock M; Ghobrial IM
Leuk Lymphoma; 2013 Jun; 54(6):1135-41. PubMed ID: 23210572
[TBL] [Abstract][Full Text] [Related]
13. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
[TBL] [Abstract][Full Text] [Related]
14. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Varga C; Xie W; Laubach J; Ghobrial IM; O'Donnell EK; Weinstock M; Paba-Prada C; Warren D; Maglio ME; Schlossman R; Munshi NC; Raje N; Weller E; Anderson KC; Mitsiades CS; Richardson PG
Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514
[TBL] [Abstract][Full Text] [Related]
15. Liquid extramedullary disease in multiple myeloma strongly predicts a poor prognosis and is associated with bortezomib resistance gene upregulation.
Ji J; Guo R; Ma J; Cui Y; Li Y; Sun Z; Li J; Fan L; Qu X
Clin Chim Acta; 2023 Aug; 548():117497. PubMed ID: 37479009
[TBL] [Abstract][Full Text] [Related]
16. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
[TBL] [Abstract][Full Text] [Related]
17. New insights into role of microenvironment in multiple myeloma.
Tricot GJ
Int J Hematol; 2002 Aug; 76 Suppl 1():334-6. PubMed ID: 12430876
[TBL] [Abstract][Full Text] [Related]
18. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
Weinstock M; Aljawai Y; Morgan EA; Laubach J; Gannon M; Roccaro AM; Varga C; Mitsiades CS; Paba-Prada C; Schlossman R; Munshi N; Anderson KC; Richardson PP; Weller E; Ghobrial IM
Br J Haematol; 2015 Jun; 169(6):851-8. PubMed ID: 25833301
[TBL] [Abstract][Full Text] [Related]
19. Association of increased microvessel density with skeletal extramedullary disease relapse in multiple myeloma patients who have skeletal extramedullary disease at diagnosis.
Yang JZ; Wu XD; Meng JB; Zhang JQ; Sun LX
Pathol Res Pract; 2018 Oct; 214(10):1694-1699. PubMed ID: 30196985
[TBL] [Abstract][Full Text] [Related]
20. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.
Hewett DR; Vandyke K; Lawrence DM; Friend N; Noll JE; Geoghegan JM; Croucher PI; Zannettino ACW
Neoplasia; 2017 Dec; 19(12):972-981. PubMed ID: 29091798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
